Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis

Surgery

Volumn 143, Issue 6, 2008, Pages 759-768

  Strong, Vivian E ^a   Kennedy, Timothy ^a   Al Ahmadie, Hikmat ^a   Tang, Laura ^a   Coleman, Jonathan ^a   Fong, Yuman ^a   Brennan, Murray ^a   Ghossein, Ronald A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADOLESCENT; ADRENALECTOMY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; MALE; MITOSIS RATE; PHEOCHROMOCYTOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR NECROSIS;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; APOPTOSIS; CELL CYCLE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TUMOR MARKERS, BIOLOGICAL;

EID: 44749091366     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.02.007     Document Type: Article

References (21)

1. Lack E.E. Pheochromocytomas. In: Rosai J., and Sobin L.E. (Eds). Tumors of the adrenal gland and extra-adrenal paraganglia. Third series (1997), Armed Forces Institute of Pathology, Washington, DC 253-254
2. Thompson L.D. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26 (2002) 551-566
3. Gerdes J., Lemke H., Baisch H., et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133 (1984) 1710-1715
4. Nagura S., Katoh R., Kawaoi A., et al. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol 12 (1999) 1107-1111
5. August C., August K., Schroeder S., et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol 17 (2004) 1119-1128
6. Gupta D., Shidham V., Holden J., and Layfield L. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Mol Morphol 8 (2000) 267-274
7. Elder E.E., Xu D., Hoog A., et al. KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16 (2003) 246-255
8. Clarke M.R., Weyant R.J., Watson C.G., and Carty S.E. Prognostic markers in pheochromocytoma. Hum Pathol 29 (1998) 522-526
9. van der Harst E., Bruining H.A., Jaap Bonjer H., et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?. J Pathol 191 (2000) 175-180
10. de Krijger R.R., van der Harst E., van der Ham F., et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 188 (1999) 51-55
11. Lam K.Y., Lo C.Y., Wat N.M., et al. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 54 (2001) 443-448
12. Luo Z., Li J., Qin Y., et al. Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas. Endocr Pathol 17 (2006) 387-398
13. Salmenkivi K., Heikkila P., Haglund C., et al. Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas. Histopathology 43 (2003) 62-71
14. Stojadinovic A., Ghossein R.A., Hoos A., et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20 (2002) 941-950
15. Neumann H.P., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346 (2002) 1459-1466
16. Hiltzik D., Carlson D.L., Tuttle R.M., et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106 (2006) 1286-1295
17. Portela-Gomes G.M., Stridsberg M., Grimelius L., et al. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies. Apmis 112 (2004) 663-673
18. Gao B., Meng F., Bian W., et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 68 (2006) 282-286
19. Pollard P.J., El-Bahrawy M., Poulsom R., et al. Expression of HIF-1alpha, HIF-2 alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91 (2006) 4593-4598
20. Watanabe T., Ichihara M., Hashimoto M., et al. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161 (2002) 249-256
21. Brouwers F.M., Elkahloun A.G., Munson P.J., et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 1073 (2006) 541-556